Clinical trials with anti-Nogo-A antibodies

Current Research Project

Summary / Zusammenfassung: In collaboration with Novartis, an anti-human Nogo-A antibody was generated and extensively tested toxicologically. A Phase I clinical trial (coordinated by Novartis, Basel) is currently ongoing in a European Network of Spinal Cord Injury Centres (EM-SCI, coordinated by Volker Dietz, Zurich), using this anti Nogo-A antibody in acutely injured paraplegic patients. For Phase II elaborate functional readouts are being developed to gain detailed information on any sensory or motor improvements occurring.
Weitere Informationen

Keywords / Suchbegriffe: neurobiology, injuries of the central nervous system, regeneration, plasticity

Project Leadership and Contacts / Projektleitung und Kontakte

Prof Dr Martin E. Schwab, PhD (Project Leader)

Funding Source(s) / Unterstützt durch: Universität Zürich (position pursuing an academic career), SNF (Personen- und Projektförderung), SNF (Programm NFS/NCCR), Foundation, Private Sector (e.g. Industry)

In Collaboration with / In Zusammenarbeit mit

Dr Anis Mir, Novartis International AG

Switzerland